-
Posted by
Two Blokes Apr 18 -
Filed in
Stock
-
2 views
- The campaign marks the successful commercial-scale PPQ completion of Asia's first 3 X 5,000L single-use bioreactors- Proprietary process innovation reduces protein cost by nearly 70% while boosting yield 20%- As the company's largest operational single-use bioreactor to date, the system triples total site capacity to 23,000L, enabling flexible scale-up solutions HANGZHOU, China , April 18, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced the successful completion of the first commercial project Process Performance Qualification (PPQ) campaign for its three sets of 5,000L single-use bioreactors (SUBs) in the second drug substance line of its MFG20 facility at the Hangzhou site. The accomplishment not only marks a significant breakthrough as Asia's first 5,000L drug substance scale-up line utilizing SUBs, but also demonstrates the company's industry-leading capabilities in single-use technology (SUT) application for large-scale production, reaffirming its position at the forefront of advanced manufacturing solutions.
